Preliminary study for high-throughput sequencing for detection of relapsed and refractory DLBCL gene mutations and drug screening

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900024343

Enrollment

Unknown

Registered

2019-07-06

Start date

2019-07-03

Completion date

Unknown

Last updated

2019-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed and refractory DLBCL gene mutation and drug screening

Interventions

Case series:Nil

Eligibility

Sex/Gender

All

Age

1 Years to 70 Years

Inclusion criteria

Inclusion criteria: Relapsed refractory DLBCL patients: 1. Recurrence: refers to the first chemotherapy after complete remission (CR) recurrence after 3 months 2. Refractory: refers to induction of chemotherapy failure or early (within 3 months) progression or repeated chemotherapy failed to obtain CR. Diagnosis can be achieved by satisfying any of the following: (1) 4 cycles of chemotherapy with standard regimen, tumor shrinkage <50% or disease progression; (2) standard chemotherapy CR, but recurrence within half a year; (3) 2 times after CR or More than 2 recurrences; (4) recurrence after hematopoietic stem cell transplantation; 2. Tumor specimens that can be genetically tested can be obtained after relapse or refractory conditions; 3. The patient has an evaluable lesion; 4. Expected to survive for more than 3 months.

Exclusion criteria

Exclusion criteria: No

Design outcomes

Primary

Measure	Time frame
safety;	—

Countries

China

Contacts

Public ContactXiaoyan Ke

Beijing Boren Hospital

dongq@borenhospital.com+86 15210562236

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026